Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026437 | 0.87 | ALDH1A1 (0.83) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL12788641 | 0.84 | ALDH1A1 (0.65) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL13804475 | 0.82 | ALDH1A1 (0.71) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL1372147 | 0.82 | CYP1A2 (0.75) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL19319095 | 0.82 | MAPK1 (0.64) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL9048604 | 0.81 | KMT2A (0.63) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL12788446 | 0.81 | HTT (0.62) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL1372144 | 0.80 | ALDH1A1 (0.73) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL3099181 | 0.80 | ALDH1A1 (0.73) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL13765975 | 0.80 | NPSR1 (0.63) | ALDH1A1NPSR1HTTMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200347068-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-10787455-B2 | Small molecule myristate inhibitors of BCR-ABL and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190084990-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20180194718-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194718-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-9840460-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840460-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170349595-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-8901169-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901169-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2011-12-22 | — | — | US | disclosed |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | disclosed |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | BCR, ABL1, MCL1 | ALDH1A1 2243/4885NPSR1 4609/4885HTT 4705/4885 |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ALDH1A1 3584/4885NPSR1 24/4885HTT 538/4885 |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | HCAR2, PCCA, MCCC2 | ALDH1A1 1159/4885NPSR1 2752/4885HTT 4288/4885 |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | ABCB11, FPR1, C5 | ALDH1A1 1135/4885NPSR1 2356/4885HTT 2777/4885 |
| US-20190084990-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ALDH1A1 1904/4885NPSR1 4566/4885HTT 4578/4885 |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ALDH1A1 2024/4885NPSR1 4623/4885HTT 4744/4885 |
| US-20200347068-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ALDH1A1 2243/4885NPSR1 4609/4885HTT 4705/4885 |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ALDH1A1 2975/4885NPSR1 4460/4885HTT 3959/4885 |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGA, OGT, UGGT1 | ALDH1A1 1153/4885NPSR1 4294/4885HTT 1171/4885 |
| US-20180194718-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ALDH1A1 3584/4885NPSR1 24/4885HTT 538/4885 |
| US-10787455-B2 | Small molecule myristate inhibitors of BCR-ABL and methods of use | BCR, ABL1, MCL1 | ALDH1A1 1904/4885NPSR1 4566/4885HTT 4578/4885 |
| US-20170349595-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND ABL AND METHODS OF USE | BCR, ABL1, ABL2 | ALDH1A1 1282/4885NPSR1 4382/4885HTT 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.